Myelodysplastic Syndrome
Azacitidine approved for treatment of myelodysplastic syndrome
Published in Medical Letter on the CDC and FDA, July 17th, 2005
"This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation) for treatment of patients with myelodysplastic syndrome.
"In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two-phase 2 single arm studies. The primary efficacy end point was the overall...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Air Pollution
Cardiorespiratory hospitalizations linked to forest fire smoke exposure - Diarrheal Disease
Developing bacterial vaccines to prevent diarrheal diseases reviewed - Food-Borne Illness
Food service workers' self-reported food preparation practices listed - Meningococcal Vaccine
Cost-effectiveness of meningococcal vaccine strategies in U.S. examined - Acne
Company receives FDA nonapprovable letter for Velac - Acute Bacterial Sinusitis
Single-dose antibiotic Zmax receives FDA approval - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
